Elizabeth L. Yanik, Srinath Chinnakotla, Sally K. Gustafson, Jon J. Snyder, Ajay K. Israni, Dorry L. Segev, Eric A. Engels – 19 January 2016 – For recipients of liver transplantations (LTs) for hepatocellular carcinoma (HCC), HCC recurrence after transplantation remains a major concern. Sirolimus (SRL), an immunosuppressant with anticarcinogenic properties, may reduce HCC recurrence and improve survival. In our study, the US Scientific Registry of Transplant Recipients was linked to pharmacy claims.

Jean‐François Dufour – 19 January 2016

Toshihiro Kitajima, Toshimi Kaido, Taku Iida, Shintaro Yagi, Yasuhiro Fujimoto, Kohei Ogawa, Akira Mori, Hideaki Okajima, Rinpei Imamine, Toshiya Shibata, Shinji Uemoto – 19 January 2016 – Hepatic venous outflow obstruction (HVOO) is a critical complication after living donor liver transplantation (LDLT). This study aimed to evaluate the incidence of HVOO and the risk factors for HVOO in adults. From 2005 to 2015, 430 adult LDLT patients (right lobe [RL] graft, 270 patients; left lobe [LL] graft, 160 patients) were enrolled and divided into no HVOO (n = 413) and HVOO (n = 17) groups.

19 January 2016

Erilia Rivera, Sameer Gupta, Blanche Chavers, Laura Quinones, Megan Rooney Berger, Sarah Jane Schwarzenberg, Timothy Pruett, Priya Verghese, Srinath Chinnakotla – 19 January 2016

Hamish Innes, Sharon J. Hutchinson, Niels Obel, Peer B. Christensen, Esther J. Aspinall, David Goldberg, Henrik Krarup, Scott A. McDonald, Allan McLeod, Amanda Weir, Lars H. Omland – 16 January 2016 – Liver mortality among individuals with chronic hepatitis C (CHC) infection is common, but the relative contribution of CHC per se versus adverse health behaviors is uncertain. We explored data on spontaneous resolvers of hepatitis C virus (HCV) as a benchmark group to uncover the independent contribution of CHC on liver mortality.

Satoru Todo, Kenichiro Yamashita, Ryoichi Goto, Masaaki Zaitsu, Akihisa Nagatsu, Tetsu Oura, Masaaki Watanabe, Takeshi Aoyagi, Tomomi Suzuki, Tsuyoshi Shimamura, Toshiya Kamiyama, Norihiro Sato, Junichi Sugita, Kanako Hatanaka, Hisashi Bashuda, Sonoko Habu, Anthony J. Demetris, Ko Okumura – 16 January 2016 – Potent immunosuppressive drugs have significantly improved early patient survival after liver transplantation (LT). However, long‐term results remain unsatisfactory because of adverse events that are largely associated with lifelong immunosuppression.

Zhi‐Feng Zhang, Zhi‐Jun Duan – 16 January 2016

Anna S. Lok – 16 January 2016

Herbert Tilg, Alexander R. Moschen, Gyongyi Szabo – 16 January 2016 – Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid accumulation in the liver accompanied by inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in a substantial subgroup of patients. At several stages in these diseases, mediators of the immune system, such as cytokines or inflammasomes, are crucially involved.